利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.02 秒)

    METHOD
    1.
    发明申请
    METHOD 审中-公开
    方法

    公开(公告)号：WO2006008526A2

    公开(公告)日：2006-01-26

    申请号：PCT/GB2005/002852

    申请日：2005-07-20

    申请人： ASTRAZENECA AB ,  ASTRAZENECA UK LIMITED ,  HUDSON, Kevin ,  SOUTH, Marie, Caroline ,  MARSHALL, Gayle ,  SAM, Mehran

    发明人： HUDSON, Kevin ,  SOUTH, Marie, Caroline ,  MARSHALL, Gayle ,  SAM, Mehran

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106

    摘要： The invention relates to a method of selecting a mammal having or suspected of having a tumour for treatment with an erbB receptor drug which comprises testing a biological sample from the mammal for expression of any one of the genes listed in Table 1 or 2 as defined herein whereby to predict an increased likelihood of response to the erbB receptor drug. Preferred genes include any one of NES, GSPT2, ETR101, TAZ, CHST7, DNAJC3, NPAS2, PIN1, TCEA2, VAMP4, DAPK1, DAPK2, MLLT3, TNNC1, KIAA0931, ACOX2, EMP1, SLC20A1, SPRY2 or PGM1.

    摘要翻译： 本发明涉及一种选择具有或怀疑具有用于治疗erbB受体药物的肿瘤的哺乳动物的方法，该方法包括测试来自哺乳动物的生物学样品以表达本文所定义的表1或2所列的任何一种基因 从而预测对erbB受体药物的响应的可能性增加。 优选的基因包括NES，GSPT2，ETR101，TAZ，CHST7，DNAJC3，NPAS2，PIN1，TCEA2，VAMP4，DAPK1，DAPK2，MLLT3，TNNC1，KIAA0931，ACOX2，EMP1，SLC20A1，SPRY2或PGM1中的任一种。

    NOVEL BIOMARKERS AND METHODS OF TREATING CANCER
    2.
    发明申请
    NOVEL BIOMARKERS AND METHODS OF TREATING CANCER 审中-公开
    新生物标记物和治疗癌症的方法

    公开(公告)号：WO2017046394A1

    公开(公告)日：2017-03-23

    申请号：PCT/EP2016/072069

    申请日：2016-09-16

    申请人： ASTRAZENECA AB

    发明人： VALDERAS, Alvaro, Avivar ,  CRUZALEGUI, Francisco, Humberto ,  HUDSON, Kevin ,  MCEWEN, Robert, Kenneth

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

    摘要： Biomarkers for the treatment of pathological conditions associated with the PI3K pathway, such as cancer, and methods of using inhibitors of upstream components of the PI3K pathway, such as PI3K-α inhibitors or AKT inhibitors, are described. In particular, there are described biomarkers for patient selection in the treatment of cancer, as well as methods of therapeutic treatment, diagnostic kits and methods of detection, wherein cancers that possess a mutation in an upstream component of the PI3K pathway (such as the PIK3CA gene and/or the AKT gene), and a wild-type MAP3K1 gene and MAP2K4 gene, are more likely to respond favourably to treatment with inhibitors of upstream components of the PI3K pathway.

    摘要翻译： 描述了用于治疗与PI3K途径相关的病理状况（例如癌症）的生物标志物，以及使用PI3K途径的上游成分抑制剂如PI3K-α抑制剂或AKT抑制剂的方法。 具体地，描述了用于治疗癌症的患者选择的生物标志物，以及治疗性治疗方法，诊断试剂盒和检测方法，其中在PI3K途径的上游成分中具有突变的癌症（例如PIK3CA 基因和/或AKT基因）和野生型MAP3K1基因和MAP2K4基因更有可能对PI3K途径的上游成分抑制剂的治疗有利。

    COMBINATION TREATMENT
    3.
    发明申请
    COMBINATION TREATMENT 审中-公开
    组合治疗

    公开(公告)号：WO2016146591A1

    公开(公告)日：2016-09-22

    申请号：PCT/EP2016/055467

    申请日：2016-03-14

    申请人： ASTRAZENECA AB

    发明人： GREEN, Stephen ,  YELLAND, Ursula, Joy ,  HUDSON, Kevin

    IPC分类号： A61K45/06 ,  A61K31/138 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4535 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/55 ,  A61K31/565 ,  A61K31/5685 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04

    CPC分类号： A61K31/497 ,  A61K31/138 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4535 ,  A61K31/506 ,  A61K31/519 ,  A61K31/55 ,  A61K31/565 ,  A61K31/5685 ,  A61K45/06 ,  A61K2300/00

    摘要： The present specification relates to the use of combinations comprising 1-(4-(5-(5- amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3- yl)piperidin-1-yl)-3-hydroxypropan-1-one (Compound [I]) or a pharmaceutically acceptable salt thereof, and either a cyclin-dependent kinase (CDK) inhibitor or an anti- estrogen agent, or both a CDK inhibitor and an anti-estrogen agent, in the treatment or prophylaxis of cancer; pharmaceutical compositions comprising Compound [I] or a pharmaceutically acceptable salt thereof and either or both of a CDK inhibitor and an anti- estrogen agent; kits comprising Compound [I] or a pharmaceutically acceptable salt thereof and either or both of a CDK inhibitor and an anti-estrogen agent, optionally with instructions for use; methods of treatment comprising the simultaneous, sequential or separate administration of Compound [I] or a pharmaceutically acceptable salt thereof and either or both of a CDK inhibitor and an anti-estrogen agent, to a warm-blooded animal, such as man; and the intermittent dosing of Compound [I] or a pharmaceutically acceptable salt thereof either alone or in combination with either or both of a CDK inhibitor and an anti-estrogen agent.

    摘要翻译： 本说明书涉及包含1-（4-（5-（5-氨基-6-（5-叔丁基-1,3,4-恶二唑-2-基）吡嗪-2-基） -1-乙基-1H-1,2,4-三唑-3-基）哌啶-1-基）-3-羟基丙-1-酮（化合物[I]）或其药学上可接受的盐，以及细胞周期蛋白 依赖性激酶（CDK）抑制剂或抗雌激素剂，或CDK抑制剂和抗雌激素剂两者均用于治疗或预防癌症; 包含化合物[I]或其药学上可接受的盐和CDK抑制剂和抗雌激素剂中的任一种或两者的药物组合物; 包含化合物[I]或其药学上可接受的盐以及任选地使用说明书的CDK抑制剂和抗雌激素剂中的任一种或两者的试剂盒; 包括将化合物[I]或其药学上可接受的盐以及CDK抑制剂和抗雌激素剂中的任一种或两者同时，顺序或分开施用于温血动物如人的治疗方法; 以及化合物[I]或其药学上可接受的盐单独或与CDK抑制剂和抗雌激素剂中的任一种或两者组合的间歇给药。